Cannabinoid hyperemesis syndrome in North America: evaluation of health burden and treatment prevalence.
Christopher N AndrewsRenata RehakMatthew WooIan WalkerChristopher MaNauzer ForbesKatherine RittenbachJoshua HathawayLynn WilsackAndy LiuYasmin NasserKeith A SharkeyPublished in: Alimentary pharmacology & therapeutics (2022)
Survey data suggest patients with CHS almost universally suffer from a cannabis use disorder, which has significant treatment implications. Treatment prevalence in the ED has increased substantially over a very short time period, with the highest rates seen during the Covid-19 pandemic.